4Shah D,Ledbetter JA,Press OW.Signaling events involved in anti-CD20 induced apoptosis of malignant human B cells[J].Cancer Im-munol Immunother,2000,48(12):673-683.
5Emer J,Wolinsky C.Rituximab a review of dermatological applications[J].J Clin Aesthetic Dermatol,2009,2(5):29-37.
6Johnson P,Glennie M.The mechanisms of action of rituximab in theelimination of tumor cells[J].Semin Oncol,2003,30(1 Suppl 2):3-8.
7Weiner GJ.Rituximab:mechanism of action[J].Semin Hematol,2010,47(2):115-123.
8Gold R,Hohlfeld R,Toyka KV.Progress in the treatment of myasthe-nia gravis[J].Ther Adv Neurol Disord,2008,1(2):99-114.
9Mantegazza R,Bonanno S,Camera G,et al.Current and emergingtherapies for the treatment of myasthenia gravis[J].NeuropsychiatrDis Treat,2011,7:151-160.
10Leandro MJ,de la Torre I.The pathogenic role of B cells in autoanti-body associated autoimmune diseases-lessons from B cell depletiontherapy[J].Clin Exp Immunol,2009,157:191-197.
